troxacitabine has been researched along with Granulocytic Leukemia, Chronic in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cortes, J; Giles, F | 1 |
| Cortes, JE; Douer, D; Estey, EH; Faderl, S; Garcia-Manero, G; Giles, FJ; Jeha, SS; Kantarjian, HM; Koller, CA; Levine, AM; O'Brien, SM; Thomas, DA | 1 |
| Albitar, M; Beran, M; Cortes, JE; Faderl, S; Feldman, EJ; Giles, FJ; Kantarjian, HM; Larson, RA; Mamus, SW; O'Brien, SM; Roboz, GJ; Talpaz, M; Verstovsek, S | 1 |
| Beran, M; Cortes, J; Freireich, EJ; Giles, FJ; Golemovic, M; Gourdeau, H; Kantarjian, H; Orsolic, N; Verstovsek, S | 1 |
| Baker, SD; Beran, M; Bivins, C; Cortes, JE; Giles, FJ; Jolivet, J; Kantarjian, HM; O'Brien, S; Smith, TL; Thomas, DA | 1 |
| Andreeff, M; Baker, SD; Bivins, C; Cortes, JE; Garcia-Manero, G; Giles, FJ; Jolivet, J; Kantarjian, HM; Miller, CB; O'Brien, SM; Thomas, DA | 1 |
1 review(s) available for troxacitabine and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
New agents in chronic myelogenous leukemia.
Topics: Angiogenesis Inhibitors; Arsenic Trioxide; Arsenicals; Cytosine; Dioxolanes; Farnesyltranstransferase; Harringtonines; Histone Deacetylase Inhibitors; Homoharringtonine; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Vaccination | 2003 |
4 trial(s) available for troxacitabine and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Topotecan; Treatment Outcome | 2003 |
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cytosine; Dioxolanes; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Salvage Therapy | 2003 |
Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Blast Crisis; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Female; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2001 |
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytosine; Dioxolanes; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 2002 |
1 other study(ies) available for troxacitabine and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Survival; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred ICR; Mice, SCID; Neoplasm Transplantation; Piperazines; Pyrimidines; Survival Analysis; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2004 |